E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Naseema Gangat,Marina Konopleva,Mrinal M. Patnaik,Elias Jabbour,Courtney D. DiNardo,Aref Al-Kali,James M. Foran,Ginna L. Granroth,Horatiu Olteanu,Tapan M. Kadia,Ayalew Tefferi,Naveen Pemmaraju +11 more
Journal ArticleDOI
Chronic myeloid leukemia--some topical issues
Journal ArticleDOI
Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Nitin Jain,Michael J. Keating,Philip A. Thompson,Jan A. Burger,Alessandra Ferrajoli,Zeev Estrov,Gautam Borthakur,Koichi Takahashi,Prithviraj Bose,Nathan Fowler,Tapan M. Kadia,Naval Daver,Marina Konopleva,Yesid Alvarado,Musa Yilmaz,Courtney D. DiNardo,Maro Ohanian,Naveen Pemmaraju,Elias Jabbour,Koji Sasaki,Rashmi Kanagal-Shamanna,Keyur P. Patel,Jeffrey L. Jorgensen,Sa A. Wang,Naveen Garg,Xuemei Wang,Katrina Sondermann,Nichole Cruz,Chongjuan Wei,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda +33 more
TL;DR: Results of the first-line cohort of an investigator-initiated phase II trial of combined IBR and VEN for pts with CLL report results of the 80 pts from the R/R CLL cohort of the trial (NCT02756897).
Journal ArticleDOI
Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation
TL;DR: The case of a 57-year-old man diagnosed with CML in 2003 in whom imatinib therapy failed after which he acquired the T315I mutation is reported, illustrating the benefit of combination therapy that includes a TKI and a second agent with a different mechanism of action, in eradicating resistant disease with the T 315I clone.
Journal ArticleDOI
Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.
Dushyant Verma,Hagop M. Kantarjian,Jenny Shan,Susan O'Brien,Amit Verma,Elias Jabbour,Srdan Verstovsek,Tapan M. Kadia,Mary Beth Rios,Jorge E. Cortes +9 more
TL;DR: The results suggest that achieving a CMR is an important endpoint for patients with CML treated with imatinib as frontline therapy, and significance in long-term outcome (event-free survival, survival, transformation), and predictive factors for CMR are suggested.